«Polyphor»
Polyphor
Company
Clinical stage, Swiss biopharmaceutical company leading the research and development of a new mechanism of action in solid tumors, CXCR4 inhibition, for combination treatment in oncology
Investors
CARB-X
Cystic Fibrosis Foundation
Novartis Venture Fund
Repair Impact Fund
Industry:
PharmTech
Headquarters:
Basel
Founded Date:
1996
Visit Website
Register and Claim Ownership